Andrew T Kuykendall

List of Publications by Year
in descending order

46 papers	532 citations	759233 12 h-index	677142 22 g-index
46 all docs	46 docs citations	46 times ranked	725 citing authors

#	Article	IF	Citations
1	Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Annals of Hematology, 2022, 101, 139-146.	1.8	17
2	Multicenter evaluation of efficacy and toxicity of venetoclaxâ€based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, .	4.1	13
3	JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer Journal, 2022, 12, 13.	6.2	9
4	A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Advances, 2022, 6, 1855-1864.	5.2	47
5	Comparison of different treatment strategies for blast-phase myeloproliferative neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.4	2
6	Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. American Journal of Hematology, 2022, 97, .	4.1	2
7	CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 774-779.	0.4	4
8	Splicing factor 3B subunit 1 <scp>(SF3B1)</scp> mutation in the context of <scp>therapyâ€related</scp> myelodysplastic syndromes. British Journal of Haematology, 2022, 198, 713-720.	2.5	3
9	Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e52-e56.	0.4	1
10	Traipsing Through Muddy Waters. Hematology/Oncology Clinics of North America, 2021, 35, 337-352.	2.2	0
11	Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 421-424.e2.	0.4	5
12	Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera. Expert Opinion on Emerging Drugs, 2021, 26, 209-218.	2.4	0
13	JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis. Journal of Immunotherapy and Precision Oncology, 2021, 4, 129-141.	1.4	4
14	Abstract CT236: A Two-Part Phase 2 Study of Itacitinib Immediate Release in Patients with Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. Cancer Research, 2021, 81, CT236-CT236.	0.9	1
15	Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research, 2021, 109, 106629.	0.8	3
16	Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leukemia Research, 2021, 109, 106640.	0.8	7
17	Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience. Blood, 2021, 138, 3612-3612.	1.4	1
18	A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes. Blood, 2021, 138, 1985-1985.	1.4	0

#	Article	IF	Citations
19	Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia. Blood, 2021, 138, 3658-3658.	1.4	0
20	Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. Blood, 2021, 138, 1984-1984.	1.4	0
21	Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e956-e960.	0.4	9
22	Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers, 2020, 12, 2278.	3.7	15
23	Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood, 2020, 135, 1696-1703.	1.4	54
24	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
25	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research, 2020, 93, 106367.	0.8	15
26	Rationale for and Results of a Phase I Study of the TGF-Î² 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial. Blood, 2020, 136, 6-8.	1.4	8
27	Driver mutationâ€specific clinical and genomic correlates differ between primary and secondary myelofibrosis. American Journal of Hematology, 2019, 94, E314-E317.	4.1	1
28	Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. Current Hematologic Malignancy Reports, 2019, 14, 543-549.	2.3	2
29	Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biology of Blood and Marrow Transplantation, 2019, 25, 1142-1151.	2.0	48
30	Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. American Journal of Hematology, 2019, 94, 87-92.	4.1	18
31	Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database. Blood, 2019, 134, 2949-2949.	1.4	2
32	CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (â‰¥60 Years Old) with Acute Myeloid Leukemia. Blood, 2019, 134, 3894-3894.	1.4	3
33	Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients â‰¥70 Years with Acute Myeloid Leukemia. Blood, 2019, 134, 1368-1368.	1.4	3
34	Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 149-149.	1.4	9
35	Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia. Blood, 2019, 134, 2636-2636.	1.4	0
36	Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis. Blood, 2019, 134, 5442-5442.	1.4	0

#	Article	IF	Citations
37	SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome. Blood, 2019, 134, 3001-3001.	1.4	1
38	Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome. Blood, 2019, 134, 4621-4621.	1.4	0
39	RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 2052-2052.	1.4	0
40	Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Annals of Hematology, 2018, 97, 435-441.	1.8	95
41	Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood, 2017, 129, 1881-1883.	1.4	54
42	The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e45-e53.	0.4	13
43	Serum Albumin as Prognostic Factor for Overall Survival in Rearranged MYC and BCL2/BCL6 Positive Double Hit Diffuse Large B Cell Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S99.	0.4	0
44	Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S91-S92.	0.4	0
45	A Diagnosis on the LAM: Pulmonary Lymphangioleiomyomatosis Masquerading as Progressive Mediastinal Lymphadenopathy. Chest, 2014, 146, 354A.	0.8	0
46	More Than a Hunch: Need for Close Follow-up and Rebiopsy When Lymphadenopathy Is Not Behaving as Predicted by Infectious Diagnosis: A Case Report. Chest, 2014, 146, 353A.	0.8	0